Immutep IMMP
NASDAQ IMMP
$4.79 +0.08 (+1.70%)
As of: Sep 30, 2026 · 9:30 AM EDT

Immutep (IMMP) EBITDA Margin (2016 - 2017)

Updated

Immutep (IMMP) recorded EBITDA Margin of -528.27% in the year ended Jun 30, 2026, up 43.60 percentage points from -571.87% a year earlier.

Analysis

Immutep (IMMP) EBITDA Margin (2016 - 2017) Analysis & Trends

Starting with the year ended Jun 30, 2010, Immutep's EBITDA Margin history includes 13 years.

  • Annual EBITDA Margin has a four-year change of +18432.47 percentage points (years ended Jun 2022 to Jun 2026).
  • The figure for the year ended Jun 30, 2026 is the highest annual EBITDA Margin since the year ended Jun 30, 2020.
  • Per Business Quant data, IMMP's EBITDA Margin was -571.87% in the year ended Jun 30, 2025 and -18960.74% in the year ended Jun 30, 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 35.95%
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 49.01%
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 6.02%
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 33.11%
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 46.01%
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -124.26%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 39.10%
10 Immutep 35.63 Mn 35.63 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2017 -811.74%
Mar 31, 2017 -160.92%
Mar 31, 2016 -894.17%
API Access

Immutep EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=IMMP&period=max&api_key=YOUR_API_KEY